Conditions

This post was originally published on this site The U.S. Food and Drug Administration has approved Mylan‘s generic version of AstraZeneca‘s Faslodex injection to be used for the same breast cancer indications as the original product, the company announced. The approval makes Mylan‘s Fulvestrant injection the third generic version of Faslodex, following the approval of…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Mateon‘s OT101 as a therapy for diffuse intrinsic pontine glioma (DIPG), a difficult-to-treat brain tumor that affects children. The designation is designed to accelerate the development of therapies that can improve the management of…

This post was originally published on this site Compass Self Storage has raised more than $100,000 this year for the Leukemia & Lymphoma Society (LLS), particularly for its children’s initiative. The $101,618 raised brings to more than $500,000 the amount Compass has donated over the years to LLS, including a local Ohio chapter. Compass is…

This post was originally published on this site Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told BioNews…

This post was originally published on this site CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission for the treatment of multiple myeloma, the company announced. The status follows the fast track designation granted in May by the U.S. Food and Drug Administration…

This post was originally published on this site Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of the patients’ response to prior treatment with platinum-based chemotherapy agents. The analysis will be presented at the…

This post was originally published on this site The first patients have been dosed in a Phase 1 trial evaluating Arvinas‘ experimental therapy ARV-471 for locally-advanced or metastatic ER-positive, HER2-negative breast cancer. Approximately 80% of newly-diagnosed breast cancers produce a protein called an estrogen receptor (ER). In these cancers, the hormone estrogen binds to its…

This post was originally published on this site I never knew what I wanted to do with my life. In fact, I’ve always been blatantly envious of people who do. I came from a family of nomadic artists, so I had a feeling I’d never be certain about my career. How could I know exactly…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib), thalidomide and dexamethasone (collectively known as VTd), to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). Darzalex is an antibody designed to recognize and block…